Eli Lilly Commits to Invest Over $1 Billion to Bolster India Manufacturing

Eli Lilly announced it will put more than $1 billion into India over the next few years, as per the news reports. The company plans to work with Indian pharmaceutical firms to expand production and strengthen supply chains.

The investment will be directed towards medicines used in obesity, diabetes, Alzheimer’s disease, cancer, and autoimmune conditions. These drugs are among Lilly’s key global therapies.

At present, Lilly does not own a plant in India. The company depends on contract manufacturers in the country that already supply complex medicines, including injectables and vials, for global use.

Launch of Mounjaro

Earlier this year, Lilly introduced its weight-loss drug Mounjaro in India. The launch came alongside Danish company Novo Nordisk’s drug Wegovy, both of which saw strong early sales growth.

India is expected to have the world’s second-largest obese population by 2050. The arrival of Mounjaro and Wegovy has increased demand for such treatments, with sales of both medicines doubling within a few months of launch.

Competition from Generics

Indian drugmakers are preparing to release cheaper versions of Wegovy once semaglutide, the drug’s main ingredient, loses patent protection next year. This is expected to create more competition in the obesity treatment segment.

The India investment follows similar moves in the United States. In September, Lilly announced a $5 billion facility in Virginia. This project is part of a $27 billion plan to add four new plants in the US over 5 years.

Read More: Best Pharma Stocks in October 2025 - Neuland Labs, Wockhardt & More – 5yr CAGR Basis! 

Hyderabad Facility

Lilly also said it will establish a new site in Hyderabad for manufacturing and quality functions. The facility will manage its Indian contract manufacturing network and provide technical support. Hiring for engineers, chemists, analysts, and quality specialists will begin immediately.

Conclusion

Eli Lilly’s $1 billion investment signals its intention to scale up operations in India, adding capacity for drug manufacturing and supply across key therapies.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.